Academic Journal
Contrastive functional connectivity defines neurophysiology-informed symptom dimensions in major depression.
| Τίτλος: | Contrastive functional connectivity defines neurophysiology-informed symptom dimensions in major depression. |
|---|---|
| Συγγραφείς: | Zhu H; Department of Bioengineering, Lehigh University, Bethlehem, PA, USA., Tong X; Department of Bioengineering, Lehigh University, Bethlehem, PA, USA., Carlisle NB; Department of Psychology, Lehigh University, Bethlehem, PA, USA., Xie H; Center for Neuroscience Research, Children's National Hospital, Washington, DC, USA., Keller CJ; Wu Tsai Neuroscience Institute, Stanford University, Stanford, CA, USA; Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, USA; Veterans Affairs Palo Alto Healthcare System, and the Sierra Pacific Mental Illness, Research, Education, and Clinical Center (MIRECC), Palo Alto, CA, USA., Oathes DJ; Center for Brain Imaging and Stimulation, Department of Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA; Center for Neuromodulation in Depression and Stress, Department of Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA; Penn Brain Science, Translation, Innovation, and Modulation Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA; Departments of Neurology, Neurosurgery, Bioengineering and Neuroscience, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA., Liu F; Department of Systems and Enterprises, Stevens Institute of Technology, Hoboken, NJ, USA., Nemeroff CB; Center for Psychedelic Research and Therapy, Department of Psychiatry and Behavioral Sciences, Dell Medical School, The University of Texas at Austin, Austin, TX, USA., Fonzo GA; Center for Psychedelic Research and Therapy, Department of Psychiatry and Behavioral Sciences, Dell Medical School, The University of Texas at Austin, Austin, TX, USA., Zhang Y; Department of Bioengineering, Lehigh University, Bethlehem, PA, USA; Department of Electrical and Computer Engineering, Lehigh University, Bethlehem, PA, USA. Electronic address: yuzi20@lehigh.edu. |
| Πηγή: | Cell reports. Medicine [Cell Rep Med] 2025 Jun 17; Vol. 6 (6), pp. 102151. Date of Electronic Publication: 2025 May 28. |
| Τύπος έκδοσης: | Journal Article |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Cell Press Country of Publication: United States NLM ID: 101766894 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2666-3791 (Electronic) Linking ISSN: 26663791 NLM ISO Abbreviation: Cell Rep Med Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: [Cambridge, MA] : Cell Press, [2020]- |
| Ιατρικοί όροι (MeSH): | Depressive Disorder, Major*/physiopathology , Depressive Disorder, Major*/diagnostic imaging , Brain*/physiopathology , Brain*/diagnostic imaging , Neurophysiology*, Humans ; Male ; Magnetic Resonance Imaging ; Female ; Adult ; Middle Aged ; Nerve Net/physiopathology ; Young Adult ; Case-Control Studies ; Principal Component Analysis |
| Περίληψη: | Competing Interests: Declaration of interests G.A.F. received monetary compensation for consulting work for SynapseBio AI and owns equity in Alto Neuroscience. C.J.K. reports equity from Alto Neuroscience. C.B.N. is a consultant for ANeuroTech (division Anima BV), Janssen Research and Development, BioXcel Therapeutics, Engrail Therapeutics, Clexio Biosciences LTD, EmbarkNeuro, Galen Mental Health LLC, GoodCap Pharmaceuticals, ITI Inc, Lucy Scientific Discovery, Relmada Therapeutics, Sage Therapeutics, Senseye Inc, Precisement Health, Autobahn Therapeutics Inc, EMA Wellness, Skyland Trail, Denovo Biopharma, and the Brain & Behavior Research Foundation. C.B.N. owns the following patents: Method and devices for transdermal delivery of lithium (US 6,375,990B1); Method of assessing antidepressant drug therapy via transport inhibition of monoamine neurotransmitters by ex vivo assay (US 7,148,027B2); and Compounds, Compositions, Methods of Synthesis, and Methods of Treatment (CRF Receptor Binding Ligand) (US 8,551, 996 B2). C.B.N. owns stock in Corcept Therapeutics, EMA Wellness, Precisement Health, Relmada Therapeutics, Signant Health, Galen Mental Health LLC, and Senseye Inc. Major depressive disorder (MDD) is highly heterogeneous, posing challenges for effective treatment due to complex interactions between clinical symptoms and neurobiological features. To address this, we apply contrastive principal-component analysis to fMRI-based resting-state functional connectivity, isolating disorder-specific variations by contrasting data from 233 MDD patients and 285 healthy controls. Subsequently, we use sparse canonical correlation analysis to identify two significant dimensions linking distinct brain circuits with clinical profiles. One dimension relates to an internalizing-externalizing symptom spectrum involving visual and limbic networks and is associated with cognitive task reaction times. The other dimension, linked to personality traits protective against depression (e.g., extraversion), is driven by dorsal attention network connections and correlates with cognitive control and psychomotor performance. This approach illuminates stable symptom dimensions and their neurophysiological underpinnings, aiding in precision phenotyping for MDD and supporting the development of targeted, individualized therapeutic strategies for mental health care. (Copyright © 2025 The Author(s). Published by Elsevier Inc. All rights reserved.) |
| Σχόλια: | Update of: bioRxiv. 2024 Oct 07:2024.10.04.616707. doi: 10.1101/2024.10.04.616707.. (PMID: 39416217) |
| References: | Nat Ment Health. 2024 Mar;2(3):287-298. (PMID: 39219688) Front Psychiatry. 2012 Feb 28;3:14. (PMID: 22403553) Nat Biomed Eng. 2021 Apr;5(4):309-323. (PMID: 33077939) J Neuropsychiatry Clin Neurosci. 2006 Summer;18(3):356-63. (PMID: 16963585) BMC Med. 2012 Dec 04;10:156. (PMID: 23210727) Psychol Sci. 2003 Jan;14(1):7-13. (PMID: 12564747) Can J Psychiatry. 1997 Apr;42(3):274-84. (PMID: 9114943) BMC Psychiatry. 2023 Jan 23;23(1):59. (PMID: 36690972) J Affect Disord. 2015 Feb 1;172:8-17. (PMID: 25451389) Assessment. 2011 Mar;18(1):27-38. (PMID: 20881102) Am J Psychiatry. 2006 Jan;163(1):73-8. (PMID: 16390892) Front Psychiatry. 2022 Mar 18;13:846201. (PMID: 35370828) Front Psychiatry. 2018 Nov 29;9:634. (PMID: 30555360) Nat Ment Health. 2024;2(2):164-176. (PMID: 38948238) Psychiatry Investig. 2009 Sep;6(3):150-5. (PMID: 20046389) J Affect Disord. 2014 Feb;155:35-41. (PMID: 24210628) Neuron. 2006 Sep 21;51(6):871-82. (PMID: 16982430) Psychiatry Investig. 2015 Apr;12(2):227-34. (PMID: 25866524) Biol Psychiatry. 2003 Sep 1;54(5):573-83. (PMID: 12946886) Netw Neurosci. 2024 Jul 01;8(2):576-596. (PMID: 38952810) Drug Alcohol Depend. 2016 Jun 01;163 Suppl 1:S37-45. (PMID: 27306730) Neuroimage. 2018 Feb 15;167:104-120. (PMID: 29155184) Cereb Cortex. 2023 Mar 10;33(6):2969-2981. (PMID: 35718539) Sci Data. 2019 Feb 12;6:180308. (PMID: 30747911) J Psychiatr Res. 2017 Sep;92:147-159. (PMID: 28458140) J Clin Psychiatry. 2011 Jun;72(6):757-64. (PMID: 21733476) Nat Methods. 2019 Jan;16(1):111-116. (PMID: 30532080) J Pers Soc Psychol. 1989 Apr;56(4):586-95. (PMID: 2709308) Am J Psychiatry. 2000 Nov;157(11):1873-5. (PMID: 11058490) Brain Struct Funct. 2015 Jul;220(4):2373-85. (PMID: 24874919) J Adolesc. 2016 Aug;51:30-40. (PMID: 27288965) Int J Methods Psychiatr Res. 2007;16 Suppl 1:S41-51. (PMID: 17623394) J Psychopharmacol. 2008 Mar;22(2):138-43. (PMID: 18308812) Science. 2022 Jun 3;376(6597):1070-1074. (PMID: 35653486) Brain Behav. 2020 Feb;10(2):e01515. (PMID: 31903706) Lancet. 2018 Apr 7;391(10128):1357-1366. (PMID: 29477251) Dev Psychopathol. 2016 Nov;28(4pt1):927-946. (PMID: 27739387) J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62. (PMID: 14399272) Cereb Cortex. 2018 Sep 1;28(9):3095-3114. (PMID: 28981612) Biol Psychiatry. 2007 Sep 1;62(5):429-37. (PMID: 17210143) Sci Data. 2016 Dec 06;3:160110. (PMID: 27922632) J Occup Environ Med. 2008 Apr;50(4):428-36. (PMID: 18404015) Front Hum Neurosci. 2022 Jan 10;15:757128. (PMID: 35082607) Biol Psychiatry. 2019 Nov 15;86(10):779-791. (PMID: 31515054) Nat Med. 2017 Jan;23(1):28-38. (PMID: 27918562) J Neural Transm (Vienna). 2008 Aug;115(8):1213-9. (PMID: 18629432) Annu Int Conf IEEE Eng Med Biol Soc. 2019 Jul;2019:3511-3514. (PMID: 31946635) J Psychiatr Res. 2016 Jul;78:11-23. (PMID: 27038550) J Neurosci. 2009 Nov 25;29(47):14980-6. (PMID: 19940193) Am J Psychiatry. 1994 Aug;151(8):1132-6. (PMID: 8037246) Sci Data. 2021 Mar 19;8(1):85. (PMID: 33741990) Schizophr Res. 2003 Nov 1;64(1):35-9. (PMID: 14511799) Lancet Psychiatry. 2017 May;4(5):409-418. (PMID: 28153641) J Cogn Neurosci. 2018 Feb;30(2):144-159. (PMID: 28984526) Br J Psychiatry. 1995 Jul;167(1):99-103. (PMID: 7551619) Nat Commun. 2018 May 30;9(1):2134. (PMID: 29849030) J Clin Psychiatry. 2011 Jun;72(6):765-74. (PMID: 21733477) Psychopharmacology (Berl). 2008 Feb;196(2):221-32. (PMID: 17909750) Arthritis Rheum. 2003 Apr 15;49(2):156-63. (PMID: 12687505) Biostatistics. 2009 Jul;10(3):515-34. (PMID: 19377034) Biol Psychiatry. 2024 Sep 15;96(6):422-434. (PMID: 38280408) Nat Commun. 2018 Aug 1;9(1):3003. (PMID: 30068943) |
| Grant Information: | R01 MH132784 United States MH NIMH NIH HHS; R01 MH125886 United States MH NIMH NIH HHS; R21 AG080425 United States AG NIA NIH HHS; R21 MH130956 United States MH NIMH NIH HHS; R01 MH129694 United States MH NIMH NIH HHS |
| Contributed Indexing: | Keywords: brain-symptom dimension; contrastive machine learning; disease heterogeneity; fMRI; functional connectivity; major depressive disorder |
| Entry Date(s): | Date Created: 20250529 Date Completed: 20250618 Latest Revision: 20250704 |
| Update Code: | 20250704 |
| PubMed Central ID: | PMC12208312 |
| DOI: | 10.1016/j.xcrm.2025.102151 |
| PMID: | 40441140 |
| Βάση Δεδομένων: | MEDLINE |
| ISSN: | 2666-3791 |
|---|---|
| DOI: | 10.1016/j.xcrm.2025.102151 |